Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals-Reference-Cited by-同舟云学术

Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals

Published:2019-09-07 Issue:10 Volume:70 Page:2213-2215
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Wasmann Roeland E¹²^ORCID,Smit Cornelis³⁴,van Dongen Eric P H⁵,Wiezer René M J⁶,Adler-Moore Jill⁷,de Beer Yvo M⁸,Burger David M¹,Knibbe Catherijne A J³⁴,Brüggemann Roger J M¹²

Affiliation:

1. Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nieuwegein, The Netherlands

2. Center of Expertise in Mycology Radboudumc/Canisius-Wilhelmina Ziekenhuis, Nijmegen, The Netherlands

3. Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands

4. Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands

5. Department of Anesthesiology, Intensive Care and Pain Management, St. Antonius Hospital, Nieuwegein, The Netherlands

6. Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands

7. Department of Biological Sciences, California State Polytechnic University, Pomona, California

8. Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center, Maastricht, The Netherlands

Abstract

Abstract In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104–177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604.

Funder

Gilead Sciences

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciz885/30109271/ciz885.pdf

Reference17 articles.

1. Liposomal amphotericin B (AmBisome®): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions;Stone;Drugs,2016

2. Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B;Groll;Clin Infect Dis,2019

3. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults;N. C. D. Risk Factor Collaboration;Lancet,2017

4. Obesity and infection;Falagas;Lancet Infect Dis,2006

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updated antimicrobial dosing recommendations for obese patients;Antimicrobial Agents and Chemotherapy;2024-05-02

2. Antibiotic Therapy for Children With Obesity;2024 Nelson’s Pediatric Antimicrobial Therapy;2024-02-12

3. Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action;Clinical Pharmacokinetics;2024-01

4. The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug Development;The Journal of Clinical Pharmacology;2023-11

5. Antibiotic Therapy for Children with Obesity;2023 Nelson’s Pediatric Antimicrobial Therapy;2023-03-01